IDH2 inhibition in AML: Finally progress? - PubMed (original) (raw)
Review
. 2015 Jun-Sep;28(2-3):112-5.
doi: 10.1016/j.beha.2015.10.016. Epub 2015 Oct 19.
Affiliations
- PMID: 26590767
- DOI: 10.1016/j.beha.2015.10.016
Review
IDH2 inhibition in AML: Finally progress?
Eytan M Stein. Best Pract Res Clin Haematol. 2015 Jun-Sep.
Abstract
Isocitrate dehydrogenase (IDH) catalyzes the conversion of isocitrate to alpha ketoglutarate. IDH occurs in three isoforms, IDH1, located in the cytoplasm, IDH2 located in the mitochondria, and IDH3, which functions as part of the TCA cycle. Mutations in the active site of IDH1 at position R132 and an analogous mutation in the IDH2 gene at position R172 have been discovered. Notably, many cases of acute myeloid leukemia (AML) have mutations in R172 and R140. The impact of these mutations and early results of inhibiting mutant IDH2 with the reversible inhibitor AG-221 are discussed in this review.
Keywords: 2-HG; Acute myeloid leukemia; Isocitrate dehydrogenase.
Copyright © 2015. Published by Elsevier Ltd.
Similar articles
- The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.
Nassereddine S, Lap CJ, Haroun F, Tabbara I. Nassereddine S, et al. Ann Hematol. 2017 Dec;96(12):1983-1991. doi: 10.1007/s00277-017-3161-0. Epub 2017 Oct 31. Ann Hematol. 2017. PMID: 29090344 Review. - Enasidenib for relapsed/refractory acute myeloid leukemia with IDH2 mutations: optimizing the patient experience.
Roboz GJ. Roboz GJ. Clin Adv Hematol Oncol. 2018 May;16(5):322-325. Clin Adv Hematol Oncol. 2018. PMID: 29851927 No abstract available. - Enasidenib for patients with relapsed acute myeloid leukemia and the IDH2 mutation.
DiNardo C. DiNardo C. Clin Adv Hematol Oncol. 2018 Apr;16(4):247-249. Clin Adv Hematol Oncol. 2018. PMID: 29742078 No abstract available. - Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.
Stein EM, DiNardo CD, Fathi AT, Pollyea DA, Stone RM, Altman JK, Roboz GJ, Patel MR, Collins R, Flinn IW, Sekeres MA, Stein AS, Kantarjian HM, Levine RL, Vyas P, MacBeth KJ, Tosolini A, VanOostendorp J, Xu Q, Gupta I, Lila T, Risueno A, Yen KE, Wu B, Attar EC, Tallman MS, de Botton S. Stein EM, et al. Blood. 2019 Feb 14;133(7):676-687. doi: 10.1182/blood-2018-08-869008. Epub 2018 Dec 3. Blood. 2019. PMID: 30510081 Free PMC article. Clinical Trial. - Enasidenib and ivosidenib in AML.
Martelli MP, Martino G, Cardinali V, Falini B, Martinelli G, Cerchione C. Martelli MP, et al. Minerva Med. 2020 Oct;111(5):411-426. doi: 10.23736/S0026-4806.20.07024-X. Epub 2020 Sep 21. Minerva Med. 2020. PMID: 32955829 Review.
Cited by
- Detection Of Mutations In The Isocitrate Dehydrogenase Genes (IDH1/IDH2) Using castPCRTM In Patients With AML And Their Clinical Impact In Mexico City.
Olarte I, García A, Ramos C, Arratia B, Centeno F, Paredes J, Rozen E, Kassack J, Collazo J, Martínez A. Olarte I, et al. Onco Targets Ther. 2019 Oct 1;12:8023-8031. doi: 10.2147/OTT.S219703. eCollection 2019. Onco Targets Ther. 2019. PMID: 31632056 Free PMC article. - Recent advances in the understanding and treatment of acute myeloid leukemia.
Watts J, Nimer S. Watts J, et al. F1000Res. 2018 Aug 6;7:F1000 Faculty Rev-1196. doi: 10.12688/f1000research.14116.1. eCollection 2018. F1000Res. 2018. PMID: 30135719 Free PMC article. Review. - Epigenetic Regulators in the Development, Maintenance, and Therapeutic Targeting of Acute Myeloid Leukemia.
Sun Y, Chen BR, Deshpande A. Sun Y, et al. Front Oncol. 2018 Feb 23;8:41. doi: 10.3389/fonc.2018.00041. eCollection 2018. Front Oncol. 2018. PMID: 29527516 Free PMC article. Review. - Targeting the cancer epigenome for therapy.
Jones PA, Issa JP, Baylin S. Jones PA, et al. Nat Rev Genet. 2016 Sep 15;17(10):630-41. doi: 10.1038/nrg.2016.93. Nat Rev Genet. 2016. PMID: 27629931 Review. - Isocitrate dehydrogenase mutations in myeloid malignancies.
Medeiros BC, Fathi AT, DiNardo CD, Pollyea DA, Chan SM, Swords R. Medeiros BC, et al. Leukemia. 2017 Feb;31(2):272-281. doi: 10.1038/leu.2016.275. Epub 2016 Oct 10. Leukemia. 2017. PMID: 27721426 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous